Thus, we show that CCR5-CCL5 axis is instrumental in recruiting Tregs and M-MDSCs to dysfunctional endothelium in the asymptomatic phase of atherosclerosis contributing to atherosclerosis progression. Drugs targeting CCR5 in asymptomatic and CAD risk-factor/s-exposed individuals might be a novel therapeutic regime to diminish atherogenesis.

Evidence of CCR5 MoA is everywhere and overwhelming.
https://pubmed.ncbi.nlm.nih.gov/39256808/

Credit Bluemoon at I Village.